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Ethnopharmacological relevance: Xie-Zhuo-Chu-Bi-Fang (XZCBF) is an empirical formula that was
developed based on the principles of traditional Chinese medicine, for the therapeutic purpose of
treating hyperuricemia. XZCBF has been clinically utilized in the Department of Traditional Chinese
Medicine at General Hospital of Guangzhou Military Command of PLA for many years and has exhibited
favorable efﬁcacy. The aim of the study is to evaluate the effects of XZCBF on the expression of uric acid
transporter 1 (URAT1) and miR-34a in hyperuricemic mice and to determine, the correlation between the
two expression levels.
Materials and methods: A hyperuricemic animal model was created by administering adenine and
allantoxanic acid potassium salt to mice. The blood uric acid levels were measured in these model mice
after treatment with XZCBF for 15 days. The potential targets of miR-34a were screened. The expression
levels of miR-34a and URAT1 in the renal tissues collected from the model mice were determined by
quantitative real-time polymerase chain reaction (qRT-PCR) analysis, and their correlation was further
established by immunohistochemistry and in situ hybridization.
Results: The uric acid levels in the model mice were signiﬁcantly higher than those in the blank controls
(Po0.05). These levels were signiﬁcantly lower in the three groups receiving different doses of XZCBF
(Po0.05), which was, in agreement with the downregulation of URAT1 and the upregulation of miR-34a
in each group. The mRNA expression level of URAT1 was positively correlated with the concentration of
uric acid but, negatively correlated with the expression level of miR-34a.
Conclusions: The ability of XZCBF to facilitate the excretion of uric acid and to lower its level in the model
group was mediated by the upregulation of miR-34a and the inhibition of URAT1 mRNA expression,
which suggests that XZCBF could be an option for the treatment of hyperuricemia in mice.
& 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Epidemiological surveys from various countries have shown
that the prevalence of hyperuricemia and gout has risen signiﬁ-
cantly, while the age of incidence has decreased (Roddy et al.,
2007; Wu et al., 2008). The asymptomatic period of hyperuricemia
is relatively long; however, deposits of uric acid salt cause injury to
tissues and internal organs, which have been closely associated
with conditions such as renal insufﬁciency, cardiovascular disease
and hyperlipidemia.
Hyperuricemia is characterized by a state of over-saturation of
extracellular urate, which is caused by a malfunction in purine
metabolism or a decrease in uric acid production. Uric acid is a
product of purine metabolism, and a large majority is excreted in
the urine through four steps, described as ultraﬁltration, reabsorp-
tion, secretion, and post-secretion reabsorption. Ninety-eight
percent of glomerular-ﬁltered uric acid is reabsorbed by the renal
tubules, a process that depends on human urate acid transporter 1
(hURAT1, SLC22A12). hURAT1 is a transporter protein that has
been shown to be closely related to the reabsorption of uric acid.
This transporter is selectively localized on the luminal surface of
the epithelial lining along the proximal renal tubules (Wang,
2004), where it maintains the electrical balance across the cell
membrane by transporting uric acid in exchange for anions (Hong
et al., 2005). Nonsynonymous mutations in the coding region of
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SLC22A12 leading to loss of function were reportedly found in
patients diagnosed with familial hypouricemia, and downregula-
tion of URAT1 could result in elevated excretion of uric acid
(Cheong et al., 2008).
The promoter of uric acid excretion, benzbromarone, is an
effective inhibitor of URAT1, which facilitates the excretion of uric
acid by directly inhibiting URAT1 on the top surface of the renal
tubules. However, benzbromarone has adverse effects including
functional impairment of the liver, gastrointestinal reactions, and
rash. Traditional Chinese medicine (TCM) has deﬁnite curative
effects in the treatment of hyperuricemia without serious adverse
effects, and an understanding of the underlying mechanism of
TCM has important practical signiﬁcance.
Xie-Zhuo-Chu-Bi-Fang (XZCBF) is an empirical formula that was
developed based on the principles of TCM and is used to treat
hyperuricemia. This formula has obtained a national invention patent
(Patent no.: ZL 2007 1 0032363.3). XZCBF consists of the following
herbs: Smilax glabra Roxb., rhizome (tu fu ling, Smilacis Glabrae
Rhizoma), Heterosmilax japonica Kunth, rhizome (bi xie, Heterosmila-
cis Rhizoma), Cremastra appendiculata (D.Don) Makino, rhizome (shan
ci gu, Cremastrae Pseudobulbus), Vaccaria hispanica (Mill.) Rauschert,
seed (wang bu liu xing, Vaccariae Semen), and Achyranthes bidentata
Blume, root (niu xi, Achyranthis Bidentatae Radix). XZCBF has been
applied clinically in the Department of TCM at General Hospital of
Guangzhou Military Command for many years, and its overall efﬁcacy
rate was statistically estimated to reach approximately 90% (Sun et al.,
2009). For more convenient use, we developed a granular form of
XZCBF: Compound Tufuling Granules (approved by Guangdong Food
and Drug Administration, license no. Guang Zhi Zi 2011-F01009).
According to the theory of Chinese Materia Medica (Chinese
Pharmacopoeia Commission, 2010), Smilax glabra Roxb., Hetero-
smilax japonica Kunth, Vaccaria hispanica (Mill.) Rauschert and
Achyranthes bidentata Blume can induce diuresis to dispel “Damp-
ness” and “Turbidity”; Smilax glabra Roxb. and Heterosmilax
japonica Kunth can smoothen joint movement to eliminate Impe-
diment; Cremastra appendiculata (D.Don) Makino, Vaccaria hispa-
nica (Mill.) Rauschert, and Achyranthes bidentata Blume can
activate “Blood” and resolve “Stasis”; Achyranthes bidentata Blume
can tonify the “Liver” and “Kidney”, and conduct “Blood” down-
ward. All of these effects are beneﬁcial in the treatment of
hyperuricemia and gout in TCM. To support the traditional use of
XZCBF, many studies on the activities of these herbs have been
performed. Smilax glabra Roxb. and its main active compound
astilbin have anti-inﬂammatory, analgesic and diuretic effects
(Zhang et al., 2004). Heterosmilax japonica Kunth can eliminate
uric acid, and it has anti-inﬂammatory and analgesic effects (Fei et
al., 2005, 2007). Colchicine, one of the active compounds in
Cremastra appendiculata (D.Don) Makino (Shi et al., 2012), is an
anti-inﬂammatory agent. In addition, it can reduce the risk of
myocardial infarction in gout patients (Crittenden et al., 2012).
Vaccaria hispanica (Mill.) Rauschert has vasodilatory effects (Jing et
al., 2007). Achyranthes bidentata Blume has restorative effects on
deﬁciencies of the immune system (Li and Li, 1997), has analgesic
and anti-inﬂammatory effects, and invigorates the circulation (Gao
et al., 2003).
Our previous study (Sun et al., 2011) demonstrated that XZCBF
lowered uric acid levels in hyperuricemic mice that were adminis-
tered adenine and allantoxanic acid potassium salt. The upstream
microRNA regulatory mechanism was also examined. MicroRNAs
are part of the long transcribed segments of RNA, and a mature
microRNA binds to an RNA-mediated silencing complex that is
similar to (or the same as) the complex that is involved in RNA
interference, resulting in the downregulation of gene expression
in vivo (Lewis et al., 2005; Wu et al., 2006). By screening microRNA
spectrum, the expression levels of 32 genes were identiﬁed as
being signiﬁcantly different, and 3 genes (miR-34a, miR-122, and
miR-146a) were closely associated with XZCBF. In addition, miR-
34a was found to be capable of binding to the 30UTR of URAT1,
which is consistent with the inhibitory role of miR-34a that was
identiﬁed in a sensor reporter assay. In this study, we located the
binding site of miR-34a in URAT1 by predicting target sites and
exploring the relationships between XZCBF, miR-34a, and URAT1
using biomedical approaches, including vector construction,
immunohistochemistry, and in situ hybridization.
2. Materials and methods
2.1. Reagents
The following reagents were acquired: 97% allantoxanic acid
potassium salt (Sigma-Aldrich, Shanghai), adenine (Sigma-Aldrich,
Shanghai), a uric acid assay kit (liquid, enzymatic method; Eastern
China Diagnostic [Shanghai] Co. Ltd), SYBR Green PCR Master Mix
(TOYOBO Company, Japan), TRIzols Reagent (Invitrogen, USA),
anti-digoxigenin-AP (Roche, Switzerland), hsa-miR-34a (Exiqon,
USA); anti URAT1 (rabbit IgG; Abbiotec, USA), secondary antibody
(DAKO ChemMate™, Denmark), and a detection kit (DAKO Envi-
sion™, Denmark).
2.2. Chemicals
The herbs we used in this study were all commercially available
as dry matter and were purchased from Nanhai Pengyang Phar-
maceutical Co., Ltd. (Table 1). These herbs were identiﬁed by
Professor Xin-Rong Wu (Pharmacy Department of General Hospi-
tal of Guangzhou Military Command, Guangzhou, China) and
Director Hui-Chan Hou (Chinese Medicine Department of Guangz-
hou Institute for Drug Control, Guangzhou, China). Voucher speci-
mens were deposited in the Herbarium of Guangzhou Institute for
Drug Control. The dosages of the herbs in XZCBF are based on the
theory of Chinese Materia Medica.
These herbs were processed into Compound Tufuling Granules
by the Pharmacy Department of General Hospital of Guangzhou
Military Command (10 g per bag, batch no.110916). The formula-
tion was extracted and puriﬁed by water extraction and an alcohol
sedimentation process (Liu et al., 2011a). The excipient of the
granules was soluble starch (Xiangtan County Starch Products Co.,
Ltd., batch number: 20110116) and granule quality was assessed by
thin layer chromatography (TLC) and high performance liquid
chromatography (HPLC) (Liu et al., 2011b). Using HPLC, the content
of ecdysterone (one main component of XZCBF) in the granules
was determined to be 0.22 mg/g.
Benzbromarone was acquired from Longdengrui Pharmaceuti-
cal (Kunshan) Co. Ltd. (batch no. 110302).
Distilled water was added at the necessary concentrations for
future use, and samples were shaken to ensure an equal distribu-
tion of the components prior to use.
Table 1
Information regarding the herbs.
Herbs Origin
(China)
Specimen
no.
Dosage
(g)
Smilax glabra Roxb., rhizome Guangxi 01-2-2-4 35
Heterosmilax japonica Kunth, rhizome Guangxi 15-1-2-1 18
Cremastra appendiculata (D.Don) Makino,
rhizome
Guizhou 08-4-1-7 15
Vaccaria hispanica (Mill.) Rauschert, seed Anhui 20-2-1-8 10
Achyranthes bidentata Blume, root Henan 16-1-2-1 10
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2.3. Equipment
A Hitachi-H7170 automatic biochemical analyzer (Hitachi, Japan), a
quantitative PCR machine (ABI PRISMs 7500 Sequence Detection
System, USA), a light microscope (Type: CX41, Olympus, Japan), a
camera system (Type: MC30, Mingmeike Sci&Tech [Guangzhou] Co.
Ltd., China), and a freezing microtome (Leica, Germany) were used.
2.4. miR-34a target -gene predictions and luciferase assay
The target genes of miR-34a were predicted by searching the
TargetScan database online, and they were conﬁrmed using the
miRanda database.
To construct the vector for the luciferase assay, the concatemer
of the miR-34a target sequence in the 30UTR of URAT1 and its
complimentary tandem sequence of “seeds” in miR-34a were
cloned downstream of the luciferase gene, which was driven by
the CMV promoter (Wu et al., 2006). The construct, together with
a miR-34a mimic or non-relevant loop, was transfected into newly
generated myocardiocytes. The cells were collected after 24 h, and
their luciferase activity was measured using an Lmax multiwell
luminometer.
2.5. Animal model and administration of chemicals
Sixty SPF Kunming male mice weighing 2872 g, provided by
the Animal Center of General Hospital of Guangzhou Military
Command, were fed normally. All of the study reports were guided
by the Animal Center of General Hospital of Guangzhou Military
Command, and the animal performance protocol was approved by
the ethics committee of the institution.
Adenine was combined with allantoxanic acid potassium salt to
create a model of hyperuricemia. The mice were randomized into
6 groups: XZCBF high-, medium- and low-dose groups; the benz-
bromarone group; the model group; and the blank control group.
Adenine (0.1 g/kg) and 97% allantoxanic acid potassium salt (0.1 g/kg)
were administered by gavage to each group (except for the blank
control group) to create the hyperuricemic model; the blank control
group was administered an equal volume of normal saline by gavage
once per day, and the treatment period was 21 days.
The therapeutic drugs were administered on the 7th day of
adenine and allantoxanic acid treatments. The corresponding
drugs were administered to the XZCBF high-, medium- and low-
dose groups, the benzbromarone group, and the model group.
Compound Tufuling (Rhizoma Smilacis Glabrae) granules at doses
of 6, 3, and 1.5 g/kg (equal to XZCBF doses of 37.5, 18.75, and
9.375 g/kg) were administered to the high-, medium- and low-
dose groups, respectively. Because drug metabolism is not exactly
the same between human and mice, we utilized 3 different doses
of XZCBF to evaluate its efﬁcacy. The concentrations of the extracts
administered were calculated based on body surface area. Adult
patients take Compound Tufuling Granules at a dose of 20 g per
day, and the average weight of an adult is 60 kg. The body surface
area conversion coefﬁcient from humans to mice is 9.03; thus the
normal dose (medium dose) of Compound Tufuling Granules
administered to mice was 20/609.03E3 g/kg. The high dose is
double the medium dose, and the low dose is half the medium
dose. The benzbromarone group received 20 mg/kg benzbromar-
one, and an equal volume of normal saline was administered to
the model and blank groups. Administration was performed once
per day by gavage, and the treatment period was 15 days.
2.6. Blood uric acid analysis
Blood was drawn from the eyes of mice on the 22nd day of the
experiment and was centrifuged in dry tubes at 3000 rpm for
10 min. The serum was separated, and the uric acid level was
determined by the uricase method (Trinder's method).
2.7. qRT-PCR analysis of URAT1 and miR-34a expression in kidney
tissue
Bilateral kidneys were harvested from the mice and pulverized
in liquid nitrogen, and total RNA was obtained with a Trizol one-
step RNA isolation kit. The expressions levels of URAT1 and miR-
34a were analyzed following the protocols described below.
The RT reaction of URAT1 was performed in an RNase-free PCR
tube using the following protocol: DEPC water was added to 1.0 μg
of total RNA to achieve a volume of 12 μL; incubation at 85 1C for
5 min; addition of 0.5 μL of Oligo(dT)(Promega), 0.5 μL of random
primer (Promega), 2.0 μL of 10 mM dNTP Mix, 0.5 μL of RNase
inhibitor, 4.0 μL of 5M-MLV RT Buffer, and 0.5 μL of M-MLV;
incubation of the 20 μL reaction solution at 30 1C for 10 min;
incubation at 42 1C for 60 min; and incubation at 85 1C for 10 min.
qRT-PCR of miR-34a was performed using the stem-loop method.
The reactions were performed in RNase-free PCR tubes as follows:
DEPC water was added to 1.0 μg of total RNA to achieve a volume of
12 μL, incubation at 85 1C for 5 min. Another solution was made in a
new RNase-free PCR tube with the following constituents: 2.0 mL of
10 mM dNTP (Promega), 0.5 mL of RNase inhibitor (Promega), 0.5 mL of
miR-34a reverse transcription primers, 0.5 mL of U6 reverse transcrip-
tion primers, 4.0 mL of 5 buffer, and 0.5 mL of M-MLV (Promega). The
solutions in the two PCR tubes were mixed and incubated at 42 1C for
60 min; then, the mixture was incubated at 85 1C for 10 min to
inactivate the reverse transcriptase.
The sequences of the synthetic primers used in quantitative
PCR are shown in Table 2. The reaction system consisted of the
following components: 5.0 μL of cDNA (1:20), 0.5 μL of forward
primer, 0.5 μL of reverse primer, 10 μL of 2 SYBR Green PCR
Master Mix, 4.0 μL of dH2O.
The URAT1 and miR-34a ampliﬁcation conditions were as
follows: pre-denaturation at 95 1C for 5 min followed by 40 cycles
of denaturation at 95 1C for 15 s, annealing at 60 1C for 15 s, and
extension at 72 1C for 32 s, with a ﬁnal extension at 72 1C for
5 min. The reaction was incubated at 4 1C for 10 min prior to plate
reading. Melting curve analysis was performed at temperatures of
60–95 1C, with measurements performed at 0.4 1C. Each sample
was assessed 3 times.
2.8. Immunohistochemistry and in situ hybridization of renal tissues
The expression of miR-34a was assessed using immunohisto-
chemistry and in situ hybridization.
For immunohistochemistry, incubation was performed at 4 1C
overnight, and secondary antibody incubation was performed at
room temperature for 30 min, followed by developed with DAB, re-
staining with hematoxylin, water washing, staining with blue dye, air
Table 2
Fluorescence quantitative PCR primer sequences.
Name Primer Sequences (50–30)
URAT1-F1 50 GAGGGAGACACGTTGACCAT
URAT1-R1 50 TTGCTTCCTAGGGCTTGCA
18s rRNA-F 50 CCTGGATACCGCAGCTAGGA
18s rRNA-R 50 GCGGCGCAATACGAATGCCCC
mmu-miR-34a-F 50 ACACTCCAGCTGGGTGGCAGTGTCTTAGCTGGT
miRNA-Ra 50 CTCAACTGGTGTCGTGGA
U6-F 50 CTCGCTTCGGCAGCACA
U6-R 50 AACGCTTCACGAATTTGCGT
a miRNA-R denoting microRNA downstream primers.
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drying, and ﬁlm sealing. The working concentration of the primary
antibody was 1:2000.
For in situ hybridization, incubationwas performed with proteinase
K (40 μg/mL) at room temperature for 20min, followed by incubation
in the pretreatment buffer for 10min, preliminary hybridization at
60 1C for 2 h, miRNA probe incubation at 90 1C for 5min, hybridization
at 60 1C overnight, sealing at room temperature for 1 h, incubation
with anti-digoxin antibody at 4 1C overnight, and staining with BCIP/
NBT in the dark for 4–48 h. The reaction was terminated with buffer at
pH 8.0. Re-staining was performed with Nuclear Fast Red, and the ﬁlm
was sealed with neutral balsam. The ﬁnal working concentration was
20 nM, and the hybridization temperature was 60 1C.
The digital images of URAT1 and miR-34a were analyzed using an
IPP image analysis software. First, the gray unit was switched to the
optical density unit in the program software, and the optical density
analysis was performed with the yellow (stained URAT1) and purple
(miR-34a -labeled) immunohistochemical stained regions as the areas
of interest (AOIs). The density (mean) and integrated optical density
(IOD) of the selected areas were measured.
2.9. Statistical analysis
The quantitative data are expressed as the mean7standard devia-
tion (x7SD). The values were converted to square roots when the
original standard error was large; multiple means were compared
using one-way analysis of variance (ANOVA); the least-signiﬁcant
difference (LSD) method was applied when the variance was equal;
and Dunnett's T3 test was performed when applied when the variance
was not equal. Pearson's correlation method was used for the correla-
tion analysis. All of the statistical analyses were performed with SPSS
software 16.0 for Windows, with a signiﬁcance level of α¼0.0500.
3. Results
3.1. Targeted inhibition of URAT1 expression by miR-34a
The target genes of miR-34a were predicted using popular
online microRNA target predicting tool: the TargetScan database. A
miR-34a binding site located in the  271–277 bp region of
URAT1, 30UTR was found, with the no.2–4 nucleotide “seeds
sequence” precisely matching the target gene sequences, which
indicated that miR-34a could inhibit the expression of URAT1. The
result was checked and conﬁrmed with those of another online
tool, miRanda. We cloned mouse URAT1, 30UTR into the multiple
restrictive sites of the report vector psi-CHECK2 to construct
recombinant vector psi-URAT1-miR34a-BS. We then cotransfected
it, together with miR-34a mimics, into HEK293 (human embryonic
kidney 293 cell line, a commonly used cell line in exogenous gene
research) (Nadeau and Kamen, 2003). By assessing the expression
level of the reporter gene, miR-34a was found to signiﬁcantly
inhibit the expression of luciferase in the psi-URAT1-miR34a-BS
construct, strongly implying that miR-34a could inhibit the
expression level of URAT1.
3.2. MiR-34a targets SLC22A12
The predicted target site of miR-34a in SLC22A12-30UTR was
consistent with the effects of miR-34a on the luciferase activity of
a luciferase- SLC22A12-30UTR reporter construct in the 293T cell
lines (a cell line derived from HEK293 cells that contains the T
antigen, resulting in higher expression of transfected genes).
Mutations in SLC22A12-30UTR disrupted the potential miR-34a
binding site, suppressing the inhibitory activity of miR-34a.
Luciferase reporter constructs with mutations at the predicted
miR-34a binding site within the SLC22A12-30UTR, were generated.
The wild-type SLC22A12-30UTR construct and its mutant counter-
part were transfected together with the negative control (NC) into
293T cells and the luciferase activity was examined 24 h after
transfection (nnPo0.01) (Fig. 1A and B).
3.3. Analysis of uric acid in urine
The blood uric acid level was 203.85743.34 μmol/L by the end
of the study period, which was signiﬁcantly different from that of
the blank control (77.88724.92 μmol/L; Po0.05). Oral adminis-
tration of XZCBF lowered the concentration of uric acid to
110.6379.30, 125.34712.23, and 163.14729.56 μmol/L in the
high-, medium- and low- dose XZCBF treatment groups, respec-
tively, showing a dose-dependent pattern and a statistically
signiﬁcant difference from the concentrations in the model group
(Po0.05). No differences were identiﬁed in either the high- or
medium- dose XZCBF treatment group or the benzbromarone
treatment group regarding the level of uric acid (Po0.05); how-
ever, a signiﬁcant difference was found between the low- dose
XZCBF treatment group and the benzbromarone treatment group
(Po0.05).
3.4. qRT-PCR analysis of URAT1 and miR-34a in kidney tissue
The relative sample template quantities (2△△Ct) of URAT1 were
calculated and compared between the groups. The original standard
error of URAT1 2△△Ct was too large, thus, the values were converted
to square roots. Based on ANOVA, the URAT1 expression level
(2.8971.13) in the blank control group was signiﬁcantly lower than
that in the other groups (Po0.05), with the exception of the
benzbromarone group. The URAT1 expression levels in the high-,
medium- and low- dose XZCBF treatment groups and the benzbro-
marone treatment group were 5.1772.17, 7.9172.40, 8.6772.71, and
4.5870.56, respectively, all of which were lower than that in the
model group (16.8273.05, Po0.05). The expression of URAT1
showed a dose-dependent pattern in the three XZCBF treatment
groups, and no difference was noted between either the high- dose
Fig. 1. Regulation of SLC22A12 by miR-34a. (A) A miR34a binding site was found in
SLC22A12- 30UTR using the microRNA target gene prediction tool TargetScan.
(B) Negative control (NC) and miR-34a mimics, a ﬁreﬂy luciferase vector containing
the wild type SLC22A12-30UTR (WT), and a ﬁreﬂy luciferase vector containing the
mutant SLC22A12-30UTR were co-transfected into 293T cells, and the luciferase
activity was assessed. nnPo0.01.
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XZCBF treatment group or the benzbromarone treatment group and
the blank control group regarding the mRNA expression level of
URAT1 (Table 3).
The relative sample template quantities (2△△Ct) of miR-34a
were calculated and compared between the groups. According to
the results of ANOVA, the level of miR-34a expression in the blank
control group (10.3274.73) was signiﬁcantly higher than that in
the other 5 groups (Po0.05). The levels of miR-34a expression in
the high-, medium- and low- dose XZCBF treatment groups and
the benzbromarone treatment group were 6.4672.19, 6.4071.28,
5.6070.93, and 6.6671.45, respectively, all of which were higher
than that in the model group (1.6170.46; Po0.05). The expres-
sion of miR-34a exhibited a dose-dependent pattern in the three
XZCBF treatment groups, and no difference in the expression level
Table 3
The expression quantities of URAT1 and miR-34a in mouse kidney tissues.
Groups N URAT1 2△△Ct (SQRT) miR-34a 2△△Ct
XZCBF high dose 10 5.1772.17n△ 6.4672.19n△
XZCBF medium dose 10 7.9172.40n△ 6.4071.28n△
XZCBF low dose 10 8.6772.71n 5.6070.93n△
Benzbromarone 10 4.5870.56n 6.6671.45n
model 10 16.8273.05 1.6170.46
Blank control 10 2.8971.13n 10.3274.73n
△Ct¼target gene Ct-internal control Ct; △△Ct¼target gene in the tested sample
△Ct-target gene in the control sample △Ct (choose the sample with the highest △Ct
if no control was included); when the ampliﬁcation efﬁciency of PCR reached 100%;
the relative sample template quantity¼2△△Ct.
n Po0.05 compared with Model; △P40.05 compared with benzbromarone.
Fig. 2. The mRNA Expression of URAT1 in renal tissues by immunohistochemistry and in situ hybridization. (A) Immunohistochemistry and in situ hybridization results.
(B) Analysis of digital images of URAT1 results by IOD. nPo0.05, compared with model. nnPo0.05, compared with blank control.
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of miR-34a was noted between the three XZCBF treatment groups
and the benzbromarone treatment group (Table 3).
3.5. Correlation analysis
We performed Pearson's correlation analysis between the uric acid
levels and the expression levels of URAT1 in the experimental mice
(r¼0.766, P¼0.000, Po0.05). The uric acid level was positively
correlated with the expression levels of URAT1 mRNA. Additionally,
we performed Pearson's correlation analysis between the expression
levels of URAT1 and miR-34a (r¼0.582, P¼0.000, Po0.05), and we
found that the expression level of URAT1 was negatively correlated
with that of miR-34a.
3.6. Immunohistochemical staining, in situ hybridization and
correlation analysis
The analysis of digital images of URAT1 immunohistochemistry
results, by IOD, revealed that the intergroup difference in URAT1
expression levels was signiﬁcant (Po0.05). The levels of URAT1
expression in the high-, medium-, and low- dose XZCBF treatment
groups were lower than that in the model group (Fig. 2A and B), while
Fig. 3. The Has-mir-34a expression in renal tissues by immunohistochemistry and in situ hybridization. (A) Immunohistochemistry and in situ hybridization results.
(B) Analysis of digital images of Has-mir-34a results by IOD. *Po0.05, compared with model. **Po0.05, compared with blank control.
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the levels of miR-34a expression in the high-, medium-, and low- dose
XZCBF treatment groups were higher than that in the model group,
indicating that XZCBF may induce the expression of miR-34a in kidney
tissue (Fig. 3A and B). This result was consistent with the gene
expression results reported above, with a similar correlation analysis
result (r¼0.656, P¼0.000).
4. Discussion
Our experiments showed that miR-34a could inhibit the
expression of URAT1 and that the target site of miR-34a was
located at position 331–338 of SLC22A12-30UTR. Moreover, the
results also demonstrated that the high, medium, and low doses of
XZCBF all lowered the uric acid levels in the hyperuricemic mice
model. URAT1 and miR-34a were universally expressed in kidney
tissue in each group; however, the mRNA expression of URAT1
tended to decrease with an increase in the therapeutic dose of
XZCBF, while the expression of miR-34a tended to increase. A
dose-dependent relationship between the uric acid level, URAT1,
and miR-34a was clearly present in all three XZCBF treatment
groups. This relationship was further supported by the results of
immunohistochemistry and in situ hybridization. Pearson's corre-
lation analysis showed that the mRNA expression levels of URAT1
were positively correlated with the uric acid level, but negatively
correlated with miR-34a expression.
Hyperuricemic animal models are important tools for studying
uric acid metabolism and associated diseases. Because uric acid
can be further degraded into allantoin by uricase in rodents, but
not in humans, it is not easy to create hyperuricemic models in
these animals. Because hyperuricemia is mainly caused by a high
intake of purine-rich food, to reduce the interspecies difference
between humans and mice, we created a hyperuricemic model by
administering 97% allantoxanic acid potassium salt and adenine by
gavage, employing the procedures described in previous studies
(Chen and Xu, 2004; Tong et al., 2009) with some modiﬁcations.
This model closely mimics the manner in which hyperuricemia
emerges in humans, and its success was supported by the clearly
elevated uric acid levels observed in our study.
According to the theory of TCM, dampness turbidity (Shizhuo)
and phlegm-static blood (Tanyu) are thought to be the major
factors in the pathogenesis of hyperuricemia. Innate insufﬁcien-
cies, cause deﬁciencies in the “Kidney” and “Spleen”, reduced
transport, the generation of dampness turbidity, and the blocking
of “Qi” and “Blood”. The blockage of “Blood” leads to a static
combination of phlegm and static blood, which is a tedious
process that involves the “Kidney”. XZCBF facilitates the excretion
of dampness turbidity and the removal of phlegm-static blood to
cure hyperuricemia and gout. Our study results showed that oral
administration of XZCBF lowered uric acid levels in a hyperur-
icemic mice model and that high-dose treatment was comparable
to benzbromarone treatment; however, medium- and low- dose
XZCBF treatment was not as effective, indicating that sufﬁcient
doses and therapeutic durations during clinical application could
ensure satisfactory clinical efﬁcacy. Our previous studies also
demonstrated that XZCBF was similar to benzbromarone with
respect to its ability to inhibit the reabsorption of uric acid
mediated by URAT1.
5. Conclusions
In summary, we conclude that XZCBF can signiﬁcantly lower
uric acid levels in a hyperuricemic animal model, which may be
mediated by its capacity to upregulate miR-34a to suppress URAT1,
resulting in improved excretion of uric acid. Thus, XZCBF may play
a role in the treatment of hyperuricemia.
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